Woodcock: Submit PRO Measures Early, Use to Check Quality of Life

Clinical Trials Advisor
A A
Drug trial sponsors developing patient-reported outcome (PRO) measures should seek FDA qualification for those tools prior to clinical trials and should use them to gauge quality of life, CDER Director Janet Woodcock advises.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00